Immunocore (NASDAQ:IMCR – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright‘s target price would suggest a potential upside of 219.69% from the company’s current price.
A number of other research analysts also recently commented on IMCR. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Morgan Stanley set a $43.00 price objective on shares of Immunocore in a research report on Friday, August 7th. Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Immunocore in a research report on Friday, August 21st. They issued an “overweight” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Immunocore currently has an average rating of “Moderate Buy” and an average target price of $56.38.
Read Our Latest Research Report on IMCR
Immunocore Stock Performance
Shares of IMCR traded up $0.30 during midday trading on Monday, reaching $31.28. The stock had a trading volume of 197,925 shares, compared to its average volume of 457,905. The firm has a 50 day simple moving average of $32.82 and a 200-day simple moving average of $31.66. Immunocore has a one year low of $27.50 and a one year high of $40.71. The firm has a market cap of $1.61 billion, a PE ratio of -84.54 and a beta of 0.81. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94.
Immunocore (NASDAQ:IMCR – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. As a group, sell-side analysts anticipate that Immunocore will post 0.04 EPS for the current year.
Institutional Trading of Immunocore
Several hedge funds and other institutional investors have recently modified their holdings of IMCR. Rockefeller Capital Management L.P. bought a new stake in shares of Immunocore during the 4th quarter worth about $47,000. GAMMA Investing LLC boosted its holdings in shares of Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after buying an additional 1,286 shares during the period. Juncture Wealth Strategies LLC bought a new stake in shares of Immunocore during the 3rd quarter worth about $207,000. denkapparat Operations GmbH bought a new stake in shares of Immunocore during the 2nd quarter worth about $209,000. Finally, Headlands Technologies LLC bought a new stake in shares of Immunocore during the 2nd quarter worth about $290,000. Institutional investors own 84.50% of the company’s stock.
Immunocore Company Profile
Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.
The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.
Recommended Stories
- Five stocks we like better than Immunocore
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
